Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. files a post-effective amendment to its Form S-1 to register 15,164,724 shares of common stock for resale by certain selling stockholders in connection with its direct listing.
The prospectus states these resales are by selling holders and the company will not receive proceeds from any sales. It notes 10,442,960 shares outstanding as of the date of this prospectus and discloses recent trading on Nasdaq under the symbol AIDX.
20/20 BioLabs, Inc. reported full year 2025 results with revenue of $2.0 million, up 17% from 2024. Gross profit rose to $0.6 million and gross margin expanded to 29.6% from 20.6%, helped by a higher mix of BioCheck and CLIAX revenue.
Operating expenses fell to $3.9 million from $6.0 million, improving the net loss to $3.7 million from $5.6 million. Cash was $1.0 million at year-end 2025, and in February 2026 the company closed a $5.0 million tranche under a preferred purchase agreement that could total up to $40 million. Management highlights a state-funded firefighter cancer screening program, deferred revenue of about $0.5 million, the launch of OneTest for Longevity and a recent Nasdaq listing as positioning the company for 2026 growth.
20/20 Biolabs, Inc. focuses on AI-powered blood tests for early detection and prevention of cancers and chronic diseases. Its main product, OneTest for Cancer, is a multi‑cancer early detection blood test run in a CAP‑accredited, CLIA‑licensed lab and positioned as an affordable “top‑of‑funnel” screen using protein tumor markers and machine learning.
The company added OneTest for Longevity in 2026 to track inflammatory biomarkers linked to chronic diseases and provide diet and lifestyle guidance using the Dietary Inflammatory Index. It also operates a Clinical Laboratory Innovation Accelerator to host third‑party lab‑developed tests and sells BioCheck field kits for suspicious powders. OneTest for Cancer generated 88% of 2025 revenue, with total shares outstanding rising to 10,442,960 as of March 30, 2026.
20/20 Biolabs, Inc. joint Schedule 13G discloses that Full Succeed International Limited is the record holder of 651,465 shares of common stock, representing 6.3% of the class based on 10,347,232 shares outstanding as of February 19, 2026. The statement is jointly filed by Full Succeed, and its directors Nengyuan Pan and Wei Lu, who share voting and dispositive power over the shares held by Full Succeed. Each individual disclaims beneficial ownership except for any pecuniary interest. The joint filing is signed and includes a Joint Filing Agreement.
20/20 Biolabs, Inc. chief executive officer Jonathan Cohen filed a Schedule 13D reporting a significant ownership stake in the company’s common stock. He beneficially owns 1,833,750 shares, including 467,350 shares he can acquire within sixty days through vested stock options.
This position represents 16.8% of the outstanding common stock, based on 10,442,438 shares outstanding as of March 3, 2026. Cohen’s holdings come from shares issued for services at the company’s formation and several stock option grants in 2000, 2023, 2024, and 2026. He states he has no current plans for corporate changes related to this stake.
20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock. The options were granted at an exercise price of $0.0000 per share and are held directly.
According to the terms, these options vest in equal quarterly installments over four years, contingent on Cohen’s continued service with the company. After this grant, he holds stock options for 352,936 shares in total, aligning his compensation more closely with the company’s long-term performance.
20/20 Biolabs, Inc. ownership filing: Streeterville Capital LLC reports beneficial ownership of 543,680 shares, representing 9.99% of the company's common stock. The filing cites 5,442,249 shares outstanding as of February 18, 2026 and attributes the position to warrants and Series E convertible preferred rights subject to a contractual 9.99% ownership cap.
The report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, who is identified as manager/sole member; voting and dispositive power is reported as sole for 543,680 shares.
20/20 Biolabs, Inc. director John Woodson Rollins reported automatic conversions of preferred stock into common shares. On February 19, 2026, 13,029 shares of Series A preferred and 6,135 shares of Series A-2 preferred were converted into an equivalent number of common shares upon the listing of the company’s common stock on the Nasdaq Capital Market. After these derivative conversions, he held 30,275 shares of common stock directly.
20/20 Biolabs, Inc. director Michael A. Ross reported an automatic conversion of preferred stock into common stock tied to the company’s listing on the Nasdaq Capital Market. On February 19, 2026, all 31 shares of Series A-2 preferred stock he held converted into 31 shares of common stock at no stated cost, leaving him with 31 common shares held directly and no remaining Series A-2 preferred shares.
20/20 Biolabs, Inc. director John G. Compton reported an automatic conversion of preferred stock into common stock. On February 19, 2026, 7,669 shares of Series A-2 preferred stock converted into 7,669 shares of common stock at a stated price of $0.00 per share upon the listing of the company’s common stock on the Nasdaq Capital Market. After this derivative conversion, Compton directly held 14,335 shares of common stock.